Stay updated on Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    Revision updated from v3.4.3 to v3.5.0.
    Difference
    0.0%
    Check dated 2026-03-19T01:15:39.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    Revision tag updated to v3.4.3; the v3.4.2 tag was removed.
    Difference
    0.0%
    Check dated 2026-03-11T19:57:37.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    No Change Detected
  5. Check
    31 days ago
    Change Detected
    Summary
    Added Overall Survival (OS) as an endpoint with follow-up up to 3 years and introduced multiple immune cell biomarkers (CD56, CD19, CD14, CD8, CD4, CD3, CD45) at various treatment-cycle timepoints. Removed prior CD8+ and CD3+ cell change endpoints measured at baseline and early post-treatment.
    Difference
    8%
    Check dated 2026-02-18T07:22:37.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2 and removed the funding-status notice and the prior Revision: v3.4.1.
    Difference
    0.4%
    Check dated 2026-02-11T05:37:57.000Z thumbnail image
  7. Check
    45 days ago
    Change Detected
    Summary
    Added a site-wide notice about potential data not being up to date due to a lapse in government funding and updated the site revision from 3.4.0 to 3.4.1.
    Difference
    0.4%
    Check dated 2026-02-04T05:34:04.000Z thumbnail image
  8. Check
    52 days ago
    Change Detected
    Summary
    The page now includes a glossary toggle and updated metadata labels, including 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0'. The previous labels such as 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4' have been removed or renamed.
    Difference
    0.2%
    Check dated 2026-01-28T03:11:44.000Z thumbnail image

Stay in the know with updates to Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial page.